Ann: Race In-person Investor Briefing Invitation Perth, page-51

"Isn't circa $3 realistically close to fair valuation for where we are at clinically?"

Sorry, but no, it's not.
1. Our AML clinical results justify a share price at least double where we are, probably triple to sextuple (ie $1Bn to $2Bn market cap)
2. For CPACS, the share price reflects a 1% chance of success or lower (see Triangle report and typical multiples for calcs); there are multiple clinical trails that you can review to satisfy yourself that CPACS is already demonstrated. In case the implication of what I'm saying isn't clear, I'm saying this: if you believe that we're a 50% chance of success then a share price of $100 per share is "realistically close to fair valuation for where we are at clinically."

As you say at the end, the only gap is it's "not official" yet. IMHO the value is $100; the price is <$2 - what does a savvy investor do in this situation?